Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model

The Original Article was published on 13 July 2018

Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-018-0150-5, published online 13 July 2018

In this article, Dr. Gary J. Bassell (gary.bassell@emory.edu) has been added as corresponding author in the web version of this article. The original article has been corrected.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Christina Gross, Shannon L. Gourley or Gary J. Bassell.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gross, C., Banerjee, A., Tiwari, D. et al. Correction to: Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model. Neuropsychopharmacol. 47, 1733 (2022). https://doi.org/10.1038/s41386-022-01345-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-022-01345-x

Search

Quick links